The ability of RNA interference (RNAi) based on injected dsRNA was investigated here for its ability to reduce the severity of pre-existing subclinical Gill-associated virus (GAV) infections in farm stocks of juvenile Black Tiger shrimp (Penaeus monodon). Following tail muscle injection of single or multiple long dsRNAs targeted to sequences positioned across the GAV ORF1a/1b replicase genes, pleopods were sampled sequentially from individuals at regular intervals over a 2 week period to track changes in GAV RNA loads by quantitative real-time RT-PCR. Mean GAV RNA amounts showed statistically significant (P <0.05) declines from Day 6 post-injection in shrimp injected with a cocktail of 5 GAV dsRNAs or a single dsRNA (dsGAV1) that targeted a ~1.2 kb sequence at the extreme 5'-terminus of the GAV genome. GAV RNA amounts were not reduced significantly among shrimp injected with another single dsRNA (dsGAV6) targeted to a sequence just downstream of the helicase motif in the ORF1b gene. Based on these encouraging data, it will be useful to determine whether the RNAi approach can reduce GAV infection loads sufficiently in P. monodon broodstock used in commercial hatcheries in Australia to restrict vertical transmission of GAV to seedstock.
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encoding a small GTPase protein (Rab7) involved in the cell endocytosis pathway in shrimp (Attasart et al., 2009; Ongvarrasopone et al., 2008; Posiri et al., 2011; Sanitt et al., 2014) , have been investigated intensively over the past decade as means of protecting shrimp against disease and mortality following virus challenge. Despite clear experimental demonstration that such RNAi approaches can be highly effective in protecting shrimp against challenge, at least transiently, as yet none have been progressed to a point where the technology can be applied commercially.
Based on observational evidence, it has become generally accepted in the shrimp aquaculture industry that most shrimp viruses are transmitted vertically, and direct experimental evidence for transmission occurring from broodstock to progeny has been obtained for viruses including Gillassociated virus (GAV) (Cowley et al. 2002) and White spot syndrome virus (WSSV) (Lo et a. 1997 ). To avoid viral infections being carried into ponds with seedstock, PCR screening of wildcaught broodstock has been used widely by the larger and more sophisticated hatcheries to detect and cull those with higher-level infections (FAO Fisheries Technical Paper No 450, 2003; Coman et al., 2013) . However, as such strategies have fallen short of providing the universal remedy for the major industries in Southeast Asia to be sustainable and profitable, in the mid 1990s, Pacific White shrimp (Litopenaeus vannamei) began to be trialled as an alternative aquaculture species to indigenous Black Tiger shrimp (Penaeus monodon) and Chinese White shrimp (Penaeus chinensis) that had become plagued by disease. With the successes seen in culturing L. vannamei in Taiwan, and upon the increasing availability of domesticated L. vannamei selected to be specific pathogen free (SPF) for viruses of most concern, the past decade has seen a massive shift to farming this species throughout the Asian region (FAO Fisheries Technical Paper No 476, 2005) .
In countries like Australia where hatcheries remain reliant mostly on locally-caught wild stocks of P. monodon broodstock and where strict government quarantine regulations preclude the import of
non-indigenous shrimp species for aquaculture, hatchery screening exclusion approaches and the establishment and maintenance of virus-free breeding populations have been the only options available for avoiding vertical transmission of viral infections to seedstock. While some progress has been made in domesticating and selectively breeding GAV-free or GAV-tolerant stocks of P. monodon in Australia (Coman et al., 2013) , many hatcheries rely on wild broodstock captured from regions where GAV is endemic and can occur at high prevalence (Cowley et al., 2000) . However, as broodstock are generally managed quite intensively in Australian hatcheries and as numbers used are relatively low, opportunities exist to inject them with virus-and/or host-specific dsRNAs to induce RNAi responses that reduce viral infection loads prior to them being mated and/or spawned to generate seedstock.
To obtain initial evidence that such a strategy is feasible and might provide a means of reducing vertical transmission of GAV from broodstock to farmed progeny, here juvenile P. monodon with subclinical GAV infections collected from a farm in North Queensland were injected with either single dsRNAs or a cocktail of 5 dsRNAs targeted to sequences across the GAV ORF1a/1b replicase gene found previously to be highly effective at protecting shrimp against disease and mortality following GAV challenge (Sellars et al., 2011) . By tracking GAV infection loads using real-time quantitative RT-PCR over a 2 week period following dsRNA injection, these were identified to be reduced significantly within 6 to 10 days among shrimp injected with the GAV dsRNA cocktail and 1 of the 2 single GAV dsRNAs examined.
Materials and Methods
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Target site positions for dsRNAs in the GAV ORF1a/1b gene, thus restricting their action to the genomic-length ssRNA transcribed in low abundance and critical for translating enzymes essential for generating genome replication machinery, were as reported previously (Sellars et al. 2011), except that the dsGAV5 target region overlapping the helicase motif in ORF1b was substituted for another region (dsGAV6; 17237-18014 nt; GenBank Acc. AF227196.2) positioned slightly further downstream ( Table 1) . As nonspecific controls, dsRNAs were designed to Penaeus merguiensis densovirus (PmergDNV) sequences used previously in RNAi bioassays (Attasart et al. 2010; and to a firefly luciferase gene sequence (De Santis et al. 2011 ; GenBank Acc. EU754723).
DNA templates used to synthesize each dsRNA were amplified by PCR using forward and reverse primers each containing T7 RNA polymerase promoter sequence extensions at their 5'-termini ( Table 1) . The GAV-specific DNA products amplified using these primers were purified through QIAquick PCR columns (QIAGEN) and dsRNA was synthesized using the MEGAscript ® T7 kit (Invitrogen) according to the manufacturer's instructions. Following quantification of a 1.5 uL aliquot of each purified dsRNA using a Nanodrop ® ND-1000 spectrophotometer (Thermo Scientific) and electrophoresis of 800 ng each dsRNA in an agarose gel to confirm its size and integrity ( Fig. 1 ), they were stored at -80°C.
Shrimp and experimental tank systems
Pleopods were sampled from juvenile Penaeus monodon collected from a total of 42 ponds across 2 farms in Northern Queensland, Australia (10 shrimp per pond, weighing 6-8 g and ~180 days old).
Of these, 4 samples from each pond were tested using a GAV TaqMan RT-qPCR ( Shrimp collected from partially-drained 5 t tanks were weighed and stocked (10 per tank) into 100 L circular tanks filled to 80 L with 24 ppt salinity seawater that was aerated, maintained at 28 ± 2°C and trickle-fed with fresh seawater at a rate of ~0.6 L min -1 . The tanks had opaque white lids and were maintained in a facility providing alternating 12 h light and 12 h dark photoperiods.
Replicates for each bioassay group were assigned to 4 tanks distributed randomly to accommodate for any position-related effects. Shrimp were fed commercial feed pellets (Ridley Aqua-feed, Melbourne, Australia) ad libitum twice each day at approximately 09:30 and 17:00 h, and waste was siphoned out 3 times per week or as required to maintain water quality. The number of shrimp alive in each tank was counted and recorded twice daily at the times of feeding, and at which times any dead shrimp observed were removed.
Tail-muscle injection of dsRNA and sampling
To deliver dsRNA, 25 µL shrimp saline solution (SSS) (450 mM NaCl, 10 mM KCl, 10 mM EDTA-2Na, 10 mM HEPES, pH to 7.3) containing each dsRNA formulation was injected into tail muscle of the 3 rd abdominal segment of each shrimp between 08:30 and 11:00 h (bioassay Day 0) using a 100 µL Hamilton glass syringe fitted with a 26-guage needle. Injection doses were
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15 µg GAV dsRNA cocktail (3 µg each of the 5 dsRNAs), 15 µg dsGAV1, 15 µg dsGAV6, 15 µg
PmergDNV dsRNAs (7.5 µg each of the 2 dsRNAs) or 4 µg of the firefly luciferase dsRNA per shrimp.
A pleopod tip (~ 5 mm in length) was sampled from each shrimp on Days 0 and 14 of the bioassay.
For shrimp in 2 of the 4 replicate tanks used for each treatment, a pleopod tip was also sampled on 
Real-time quantitative (q)RT-PCR
Pleopod tissue was removed from RNALater TM solution with sterile forceps, blotted dry briefly on sterile absorbent paper towel and homogenized in a tube containing 600 µL TRIzol ® reagent (Invitrogen) and 3 glass beads using a FastPrep FP120 tissue grinder (Savant). Total RNA was then extracted according to the standard TRIzol protocol. Dried RNA was resuspended in 15 µL RNasefree water and before being stored at -80C, a 1.5 µL aliquot was examined using a Nanodrop ® ND-
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1000 spectrophotometer to determine the RNA concentration and relative purity. cDNA was synthesized in a 10 μL reaction containing 500 ng total RNA, 50 ng random hexamers and 100 U SuperScriptTM-III reverse transcriptase (Invitrogen) according to the manufacturer's protocol. A TaqMan RT-qPCR test for GAV (de la Vega et al., 2004) was performed as described except that 2 µL cDNA (equivalent to 100 ng total RNA) was used in a 20 µL reaction prepared using TaqMan® Universal PCR Master Mix (Applied Biosystems) and 900 nM each PCR primer. From this 20 µL mixture, 3 x 5 µL aliquots were placed into 3 wells of a 384-well PCR plate as plate replicates. PCR was performed in an ABI Prism® 9700HT Sequence Detection System (Applied Biosystems) using default thermal cycling conditions. To quantify GAV RNA copy numbers accurately, cDNA prepared to a 10-fold dilution series of synthetic GAV RNA of know copy number was amplified in the same plate to generate a linear regression plot of mean cycle threshold (Ct) value vs RNA copy number. Infection loads were expressed as GAV RNA copies per 1 ng total RNA to adjust for the use of cDNA prepared to 25 ng total RNA in each 5 µL reaction aliquot.
RT-qPCR was performed initially on RNA extracted from each Day 0 pleopod sample, and only those shrimp identified to possess higher GAV RNA amounts were selected to determine relative changes in infection loads over time following injection of the various dsRNAs. GAV infection loads were tracked over the 14 day bioassay period for 11 shrimp injected with the GAV dsRNA cocktail, 9 injected with dsGAV1, 9 injected with dsGAV6, 6 injected with PmergDNV dsRNA and 7 injected with luciferase dsRNA.
Statistical analyses
Shrimp survival among treatment groups was compared using repeated measures analysis of variance (ANOVA; PROC GLM; SAS Institute Software, 1999). GAV RNA copy number data were adjusted to log 10 scale for standardization, tested for normality and homogeneity using Q-Q
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plot analysis, and fitted to a linear regression model using R Software (V3.00). To compare changes between data collection points, a mixed-effects model one-way ANOVA with Tukey post-hoc test was used. P values ≤0.05 were considered statistically significant. Mean GAV RNA copy numbers were assessed to be significantly reduced at bioassay sampling points relative to mean RNA copy numbers detected among pleopods of shrimp sampled at Day 0 immediately prior to dsRNA injection.
Results & Discussion
Among the 5 groups of juvenile Penaeus monodon injected with the dsRNAs specific to GAV, PmergDNV or firefly luciferase, very few deaths occurred over the 14 day bioassay (Fig. 2) .
Similarly low numbers of mortalities also occurred among any of the shrimp handled and biopsied regularly over the 14 day period (data not shown). As RT-qPCR data on pleopods sampled from all shrimp immediately prior to dsRNA injection (Day 0) and from selected shrimp thereafter identified none with moderate to high GAV RNA copy numbers (data not shown), and as no gross signs of GAV disease became evident in any shrimp, the mortalities that did occur were most likely due to non-specific causes.
Among the 11 P. monodon injected with the cocktail of 5 GAV dsRNAs and tracked regularly by RT-qPCR over the 14 day bioassay, mean GAV RNA amounts detected on Day 0 dropped progressively to be significant (P <0.05) on Day 10 (Fig. 3) . Similarly, among the 9 shrimp injected with dsGAV1 targeted to 5'-terminus of the GAV genome, mean GAV RNA amounts showed a slightly more dramatic decline to be significant (P <0.01) on Day 6 compared to Day 0, with further drops on Days 10 and 14 being statistically significant (P <0.01) compared to Days 0 and 3. While mean GAV RNA amounts appeared to decline somewhat over the 14 day trial among the 9 shrimp
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tracked following injection with dsGAV6 targeted to an ORF1b gene region just downstream of the helicase motif, at no time point was the quantum of decline significant compared to Day 0. No significant declines in mean GAV loads became evident among the 6 shrimp tracked following injection of the 2 PmergDNV dsRNAs or the 7 shrimp tracked following injection of the firefly luciferase dsRNA (Fig. 3) .
The GAV RT-qPCR data generated for pleopods biopsied progressively from shrimp indicated that GAV replication was being suppressed significantly following injection of the GAV dsRNA cocktail and dsGAV1. These trends were evident even amidst the variability in GAV infection loads among the individuals examined and them being an order of magnitude or more below what would have been ideal to accurately quantify changes above biological and technical noise. For example, at such low infection loads, how GAV is distributed in different pleopods might be expected to vary relatively more than in individuals with higher-level infections (Do 2012). The relative technical consistency in RT-qPCR test will also be lower when RNA template numbers are low. Having more juvenile P. monodon with higher-load GAV infections would have avoided these problems and moved RNAi-mediated effects further above the noise threshold. However, despite the limitations imposed by the shrimp available for use, the clear reductions in GAV RNA amounts noted from 6 to 10 days after injection of the GAV dsRNA cocktail and the single dsGAV1, and similar reports of the use of virus-specific dsRNA to reduce or clear pre-existing shrimp infections by densoviruses and YHV (Attasart et al., 2011; Ho et al., 2011; Posiri et al., 2011) , provides encouragement for trialling this RNAi approach with wild broodstock used in commercial hatcheries to determine whether similar or greater reductions in GAV infection loads can be achieved.
The ability of tail muscle injection of a cocktail of 5 dsRNAs targeted to regions in the GAV ORF1a/1b gene, and thus the genomic-length RNA replicated in low abundance relative to the 2
sub-genomic mRNAs, to reduce loads of pre-existing subclinical GAV infections in juvenile P.
monodon is consistent with its ability to protect P. monodon against disease following challenge with GAV (Sellars et al. 2011) . The finding that the single dsGAV1 dsRNA targeted to the extreme 5'-terminus of the GAV genome reduced infection loads slightly more rapidly and substantially was interesting, and in a practical context would reduce complexity and cost of dsRNA production in any commercial application of technology. As the promoter for the viral RNA-dependant RNA polymerase needed to replicate the GAV genomic ssRNA is likely to reside at or near the 3'- is not unexpected that a dsRNA targeted to this part of the genome would profoundly inhibit transcription of genomic ssRNA as well as ribosomal translation of non-structural ORF1a/1b gene proteins critical for generating the functional enzymes needed to replicate the viral genome (Ziebuhr 2008) . As dsRNA targeted to the PmRab7 mRNA of P. monodon has also been shown to be extremely effective in inhibiting replication of viruses such as YHV and WSSV (Attasart et al., 2009 , Posiri et al 2011 Sanitt et al., 2014) , and to enhance RNAi mediated by virus-specific dsRNAs, it will be worth exploring whether injection of dsGAV1 together with PmRab7 dsRNA will further improve its efficacy in inhibiting GAV infection.
The RNAi approach described here has potential to be applied commercially in hatcheries using wild broodstock captured from regions such as North Queensland where GAV is endemic and can occur at high prevalence (Cowley et al. 2000) . If pre-existing GAV infections can be reduced appreciably prior to broodstock mating and/or spawning, this might provide a means of restricting vertical transmission of infections to progeny seeded into ponds. As GAV can be transmitted from males or females (Cowley et al. 2002) , all broodstock would need to be treated. If used in combination with PCR screening to eliminate broodstock with higher level GAV infections, this
RNAi approach might also assist in eliminating GAV infections from domesticated breeding
populations (Coman et al 2013) . With these goals in mind, trials are now underway to determine whether injection of GAV dsRNA can reduce infection loads in P. monodon broodstock similarly without impacting their fecundity, and whether this approach can mitigate vertical transmission of GAV to progeny. GGCCTAATACGACTCACTATAGGGAGTGAGAGAACAGGATATGCCGGTGT 13818-13843 T7-dsGAV-6F GGCCTAATACGACTCACTATAGGGCATTTCCCCCATAACACCAG 16489-16508 T7-dsGAV-6R
GGCCTAATACGACTCACTATAGGGGTGACGAGGATGGCAAAGTT 17267-17286 T7-dsDNV-ns1F GGCCTAATACGACTCACTATAGGGTTACATTTTACTCTGGTATTATTGT T7-dsDNV-ns1R GGCCTAATACGACTCACTATAGGGCCCTAGAACTGCTTAACCTTA T7-dsDNV-vp1F GGCCTAATACGACTCACTATAGGGCCAAGGTAAACGAAAGAGTAAGC T7-dsDNV-vp1R GGCCTAATACGACTCACTATAGGGATACTTCTTGGCGTTCTCTATCTG T7-Luc-dsRNA-F GAATTTAATACGACTCACTATAGGGATCGCGCCATTCTATCCTCTA T7-Luc-dsDNA-R GAATTTAATACGACTCACTATAGGGATCTACATCGACTGAAATCCCT a PCR primer positions in the GAV genome (GenBank Acc: AF227196) are indicated. 
